Anthem Biosciences Limited
Fundamental Score
Anthem Biosciences Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of ANTHEM across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (20.83%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.50%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (38.78%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Consistent Growth Track Record (23.86% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Profit Growth Track Record (37.27% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (63.42x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹576.31 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.69%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
6 factors identified
Premium Valuation Risk (P/E: 79.93x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Weak Earnings Growth (-40.74% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Limited Institutional Interest (FII+DII: 8.87%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Financial Statements
Comprehensive financial data for Anthem Biosciences Limited
About ANTHEM
Business Overview
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
Company Details
Key Leadership
Latest News
ANTHEM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Anthem Biosciences Limited (ANTHEM)?
As of 29 Jan 2026, 10:37 am IST, Anthem Biosciences Limited (ANTHEM) is currently trading at ₹592.85. The stock has a market capitalization of ₹37.01K (Cr).
Is ANTHEM share price Overvalued or Undervalued?
ANTHEM is currently trading at a P/E ratio of 79.93x, compared to the industry average of 51.82x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Anthem Biosciences Limited share price?
Key factors influencing ANTHEM's price include its quarterly earnings growth (Sales Growth: 4.78%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Anthem Biosciences Limited a good stock for long-term investment?
Anthem Biosciences Limited shows a 5-year Profit Growth of 37.27% and an ROE of 20.83%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.04 before investing.
How does Anthem Biosciences Limited compare with its industry peers?
Anthem Biosciences Limited competes with major peers in the Biotechnology. Investors should compare ANTHEM's P/E of 79.93x and ROE of 20.83% against the industry averages to determine its competitive standing.
What is the P/E ratio of ANTHEM and what does it mean?
ANTHEM has a P/E ratio of 79.93x compared to the industry average of 51.82x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹80 for every ₹1 of annual earnings.
How is ANTHEM performing according to Bull Run's analysis?
ANTHEM has a Bull Run fundamental score of 63.7/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does ANTHEM belong to?
ANTHEM operates in the Biotechnology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Anthem Biosciences Limited.
What is Return on Equity (ROE) and why is it important for ANTHEM?
ANTHEM has an ROE of 20.83%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Anthem Biosciences Limited generates profits from shareholders' equity.
How is ANTHEM's debt-to-equity ratio and what does it indicate?
ANTHEM has a debt-to-equity ratio of 0.04, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is ANTHEM's dividend yield and is it a good dividend stock?
ANTHEM offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has ANTHEM grown over the past 5 years?
ANTHEM has achieved 5-year growth rates of: Sales Growth 23.86%, Profit Growth 37.27%, and EPS Growth -40.74%.
What is the promoter holding in ANTHEM and why does it matter?
Promoters hold 74.69% of ANTHEM shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is ANTHEM's market capitalization category?
ANTHEM has a market capitalization of ₹37009 crores, placing it in the Large-cap category.
How volatile is ANTHEM stock?
ANTHEM has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for ANTHEM?
ANTHEM has a 52-week high of ₹N/A and low of ₹N/A.
What is ANTHEM's operating profit margin trend?
ANTHEM has a 5-year average Operating Profit Margin (OPM) of 38.78%, indicating the company's operational efficiency.
How is ANTHEM's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 4.78% and YoY Profit Growth of 7.10%.
What is the institutional holding pattern in ANTHEM?
ANTHEM has FII holding of 1.66% and DII holding of 7.21%. Significant institutional holding often suggests professional confidence in the stock.